BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma C, Kotze PG, Almutairdi A, Jairath V, Panaccione R. Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. Clin Gastroenterol Hepatol 2019;17:2374-2376.e2. [PMID: 30528845 DOI: 10.1016/j.cgh.2018.11.062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Mak JWY, Yuen NTK, Yip TCF, Lam RHM, Lam BKH, Cheng CTY, Wong GLH, Chan FKL, Ng SC. No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study. J Gastroenterol Hepatol 2022. [PMID: 35338526 DOI: 10.1111/jgh.15838] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shaffer SR, Rubin DT. Response to Tetangco and Hanauer. Am J Gastroenterol 2021;116:1959-60. [PMID: 34101668 DOI: 10.14309/ajg.0000000000001330] [Reference Citation Analysis]
3 Yadav V, Mai Y, McCoubrey LE, Wada Y, Tomioka M, Kawata S, Charde S, Basit AW. 5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease. Biomedicines 2021;9:578. [PMID: 34065300 DOI: 10.3390/biomedicines9050578] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
4 Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol 2021;116:125-33. [PMID: 32947317 DOI: 10.14309/ajg.0000000000000847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Frias Gomes C, Chapman TP, Satsangi J. De-escalation of medical therapy in inflammatory bowel disease. Curr Opin Pharmacol 2020;55:73-81. [PMID: 33160250 DOI: 10.1016/j.coph.2020.09.014] [Reference Citation Analysis]
6 Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther 2020;52:481-91. [PMID: 32573825 DOI: 10.1111/apt.15876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Chapman TP, Frias Gomes C, Louis E, Colombel J, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:73-84. [DOI: 10.1111/apt.15771] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
8 Choi YI, Kim TJ, Park DK, Chung JW, Kim KO, Kwon KA, Kim YJ. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease. Int J Colorectal Dis. 2019;34:1713-1721. [PMID: 31471699 DOI: 10.1007/s00384-019-03368-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clin Gastroenterol Hepatol 2020;18:1152-1160.e1. [PMID: 31419574 DOI: 10.1016/j.cgh.2019.08.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
10 Scott FI, Singh S. Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win. Clin Gastroenterol Hepatol 2019;17:1726-8. [PMID: 30630101 DOI: 10.1016/j.cgh.2018.12.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]